Grupo Espanol De Tumores Neuroendocrinos
Clinical trials sponsored by Grupo Espanol De Tumores Neuroendocrinos, explained in plain language.
-
New targeted radiation therapy takes on standard drug for rare lung and thymus cancers
Disease control Recruiting nowThis phase 3 trial tests whether a targeted radiation therapy (177Lu-edotreotide) works better than a standard drug (everolimus) for people with advanced neuroendocrine tumors of the lung or thymus. About 170 adults with well- or moderately-differentiated tumors will be randomly …
Phase: PHASE3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Can spacing out cancer therapy reduce harm without losing control?
Disease control Recruiting nowThis study compares two schedules of a radioactive drug (Lu177-Dotatate) for people with slow-growing, advanced midgut neuroendocrine tumors. One group gets treatment every 8 weeks, the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-rela…
Phase: PHASE3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for rare, aggressive cancers: immune therapy targets hard-to-treat tumors
Disease control Recruiting nowThis study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin, a rare and aggressive cancer with limited treatment options. About 87 partici…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC